Page 27 - Serum Institute Of India

Govt to ensure regulatory facilitation for Serum's Covid-19 vaccine trials

Serum Institute of India, the largest vaccine manufacturer in the world, has been chosen by Oxford and its partner AstraZeneca to manufacture the vaccine once it gets ready.

We want to price Covid-19 vaccine below Rs 1,000: Serum Institute CEO

Pune's Serum Institute of India is placing its bets on the Oxford-AstraZeneca vaccine candidate AZD1222

Serum Institute to begin trials of Oxford's Covid-19 vaccine by August-end

The varsity has tied up with Serum Institute of India (SII) to manufacture and supply the vaccine to India and over 60 other countries having a combined population of 3 billion

Serum Institute to apply for trials on Oxford's Covid-19 vaccine soon: CEO

SII, the largest vaccine manufacturer in the world, has been chosen by Oxford and its partner AstraZeneca to manufacture the vaccine once it gets ready

Indian pharma can produce Covid-19 vaccines for entire world: Bill Gates

India's challenge immense in coronavirus crisis immense because of its large population, says billionaire philanthropist

Serum Institute of India expects to develop Covid-19 vaccine by year-end

Poonawalla further said that till the vaccine comes, testing is the key and that is why SII has invested in MyLabs

Covid-19 crisis: Race to develop vaccine gets a booster as field widens

On Thursday, CDSCO also approved Zydus Cadila's plasmid DNA vaccine candidate ZyCoV-D, developed at its Vaccine Technology Centre in Ahmedabad.

Jeff Bezos, Mukesh Ambani rise in wealth report on coronavirus times

China-based Hurun Research's report tracks wealth changes of successful entrepreneurs in the four months ending May 31.

Shot of Hope: Equal access a hurdle after race to coronavirus vaccine

The second of a two-part series examines challenges linked to IPR and monopoly once Covid-19 vaccine is created

Covid-19 vaccine development moving positively, says Bharat Biotech CEO

He expressed satisfaction on the progress of the research connected with the vaccine development so far, but insisted that "in science, things can change"

Serum Institute hopes to roll out a Covid-19 vaccine. Is this realistic?

The Pune-based company plans to start trials on people to assess whether the Bacille Calmette-Guerin (BCG) vaccine for tuberculosis can also protect against the Covid-19 virus.

India to test 100-yr-old vaccine on adults as war on Covid-19 hots up

The 100-yr old vaccine has an established safety profile; if effective, it can hit the market within this year

Serum Institute acquires Czech firm to expand polio vaccine capabilities

Serum Institute is widening its manufacturing footprint and launching new products as it aims to consolidate its position as the world's largest vaccine manufacturer by volume. On Tuesday, Pune-based Serum Institute acquired Czech arm of US firm Nanotherapeutics for 72 million Euros (around Rs 500 crore) as a part of its growth strategy. This is its second overseas acquisition in five years and move will quadruple its injectable polio dosage capacity to 200 million doses annually by 2019. The company will invest another 40 million Euros (about Rs 280 crore) to upgrade Nanotherapeutics's manufacturing plant over the next two years. At present the plant is idle."This acquisition complements our facility in Netherlands which we acquired five years ago and will increase our injectable polio vaccine capability four times to 200 million doses. While there is a requirement of 300 million doses each year globally there is production capacity of only 100 million and we will be able to ...

Serum hunts for acquisitions

The chief executive officer of Asia's largest vaccine maker said he will consider selling a stake to private equity investors as he hunts for acquisitions in preparation for a bout of consolidation to hit the industry over the next few years.Closely held vaccine maker Serum Institute of India Pvt. Ltd. has the ability to raise as much as $3 billion through a combination of debt and equity, Chief Executive Officer Adar Poonawalla said in an interview. He declined to say which companies he expects to come up for sale but added in an e-mail that no other vaccine firm in the developing world would be worth more than $1 billion. He doesn't foresee having to spend more than that for an acquisition, while leaving open the possibility of doing more than one deal.The company scrapped plans to sell a 5 to 10 percent stake to private equity investors last year at a $12 billion valuation partly because the acquisitions the funds were needed for were taken off the market, Poonawalla said. As low va